Rekha Vij1, Imre Noth2, Mary E Strek1. 1. Section of Pulmonary and Critical Care Medicine, the Department of Medicine, University of Chicago, Chicago, IL. 2. Section of Pulmonary and Critical Care Medicine, the Department of Medicine, University of Chicago, Chicago, IL. Electronic address: inoth@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND: Patients with interstitial lung disease (ILD) may have features of an autoimmune disorder that do not meet the diagnostic criteria for connective tissue diseases. We determined the prevalence and characteristics of autoimmune-featured ILD (AIF-ILD) and compared these with those of idiopathic pulmonary fibrosis (IPF) and known connective tissue disease-related ILD (CTD-ILD). METHODS: Patients with ILD who did not meet the criteria for a connective tissue disease were defined as having AIF-ILD if they had a sign or symptom suggestive of a connective tissue disease and a serologic test reflective of an autoimmune process. Clinical characteristics, high-resolution CT images, and lung biopsy specimens were analyzed and compared with those of patients with IPF and CTD-ILD. Survival was evaluated using a Kaplan-Meier curve. RESULTS: Two hundred subjects completed the questionnaire and serologic testing. AIF-ILD was identified in 32%, IPF in 29%, and CTD-ILD in 19%. Gender, age, and race differed among groups (P < .01). Sixty-two percent of patients with AIF-ILD had a typical usual interstitial pneumonia (UIP) pattern on CT images. In 31 patients with AIF-ILD, lung biopsy specimens showed UIP in 81% and nonspecific interstitial pneumonia in 6%. Patients with AIF-ILD and IPF had similar survival, worse than those with CTD-ILD (P < .01). Antinuclear antibody (ANA) titers ≥ 1:1280 were associated with improved survival in patients with AIF-ILD (P = .02). CONCLUSIONS: Systematic evaluation of symptoms and serologic tests in ILD can identify AIF-ILD. A UIP pattern on CT images and histopathology is common in AIF-ILD. Although survival for patients with AIF-ILD is poor, ANA titers ≥ 1:1280 are associated with improved survival.
BACKGROUND:Patients with interstitial lung disease (ILD) may have features of an autoimmune disorder that do not meet the diagnostic criteria for connective tissue diseases. We determined the prevalence and characteristics of autoimmune-featured ILD (AIF-ILD) and compared these with those of idiopathic pulmonary fibrosis (IPF) and known connective tissue disease-related ILD (CTD-ILD). METHODS:Patients with ILD who did not meet the criteria for a connective tissue disease were defined as having AIF-ILD if they had a sign or symptom suggestive of a connective tissue disease and a serologic test reflective of an autoimmune process. Clinical characteristics, high-resolution CT images, and lung biopsy specimens were analyzed and compared with those of patients with IPF and CTD-ILD. Survival was evaluated using a Kaplan-Meier curve. RESULTS: Two hundred subjects completed the questionnaire and serologic testing. AIF-ILD was identified in 32%, IPF in 29%, and CTD-ILD in 19%. Gender, age, and race differed among groups (P < .01). Sixty-two percent of patients with AIF-ILD had a typical usual interstitial pneumonia (UIP) pattern on CT images. In 31 patients with AIF-ILD, lung biopsy specimens showed UIP in 81% and nonspecific interstitial pneumonia in 6%. Patients with AIF-ILD and IPF had similar survival, worse than those with CTD-ILD (P < .01). Antinuclear antibody (ANA) titers ≥ 1:1280 were associated with improved survival in patients with AIF-ILD (P = .02). CONCLUSIONS: Systematic evaluation of symptoms and serologic tests in ILD can identify AIF-ILD. A UIP pattern on CT images and histopathology is common in AIF-ILD. Although survival for patients with AIF-ILD is poor, ANA titers ≥ 1:1280 are associated with improved survival.
Authors: I Yamadori; J Fujita; S Bandoh; M Tokuda; Y Tanimoto; M Kataoka; Y Yamasaki; T Yoshinouchi; Y Ohtsuki; T Ishida Journal: Rheumatol Int Date: 2002-05-29 Impact factor: 2.631
Authors: Gary W Hunninghake; David A Lynch; Jeffrey R Galvin; Barry H Gross; Nestor Müller; David A Schwartz; Talmadge E King; Joseph P Lynch; Richard Hegele; James Waldron; Thomas V Colby; James C Hogg Journal: Chest Date: 2003-10 Impact factor: 9.410
Authors: W W Douglas; H D Tazelaar; T E Hartman; R P Hartman; P A Decker; D R Schroeder; J H Ryu Journal: Am J Respir Crit Care Med Date: 2001-10-01 Impact factor: 21.405
Authors: Kevin R Flaherty; Thomas V Colby; William D Travis; Galen B Toews; Jeanette Mumford; Susan Murray; Victor J Thannickal; Ella A Kazerooni; Barry H Gross; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-02-20 Impact factor: 21.405
Authors: Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2017-04-28 Impact factor: 0.670
Authors: Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Matthew J Strand; David Sprunger; Gregory P Cosgrove; Evans R Fernandez-Perez; Stephen K Frankel; Tristan J Huie; Amy L Olson; Joshua Solomon; Kevin K Brown; Jeffrey J Swigris Journal: Chest Date: 2014-09 Impact factor: 9.410
Authors: Ayodeji Adegunsoye; Justin M Oldham; Carley Demchuk; Steven Montner; Rekha Vij; Mary E Strek Journal: Respir Med Date: 2016-03-21 Impact factor: 3.415